Mimedx (MDXG) Income from Continuing Operations (2011 - 2026)
Mimedx (MDXG) posted Income from Continuing Operations of 14840000.0 for Q2 2026, down 36.65% sequentially from 10860000.0 in Q1 2026, and down 254.29% YoY from 9618000.0 in Q2 2025.
Mimedx (MDXG) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Mimedx has reported Income from Continuing Operations for 16 years, with the latest figure at 14840000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 254.29% year-over-year to 14840000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 6239000.0 (down 80.48% YoY) and the FY2025 annual result came in at 48578000.0, up 15.67% from the prior year.
- Income from Continuing Operations retreated to 14840000.0 in Q2 2026 per MDXG's latest filing, from 10860000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 51288000.0 in Q4 2023 and troughed at 14840000.0 in Q2 2026.
- A 5-year average of 6242444.44 and a median of 8360000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 4839.7% in 2022, down 510.91% in 2022.
- Over 5 years, Income from Continuing Operations stood at 9830000.0 in 2022, then jumped by 421.75% to 51288000.0 in 2023, then sank by 85.5% to 7438000.0 in 2024, then jumped by 104.24% to 15191000.0 in 2025, then sank by 197.69% to 14840000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 14840000.0, 10860000.0, and 15191000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | -14.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.84 Mn |
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | 15.19 Mn |
| Sep 30, 2025 | 16.75 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 7.44 Mn |
| Sep 30, 2024 | 7.88 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 9.06 Mn |
| Dec 31, 2023 | 51.29 Mn |
| Sep 30, 2023 | 8.84 Mn |
| Jun 30, 2023 | 9.25 Mn |
| Mar 31, 2023 | -1.94 Mn |
| Dec 31, 2022 | 9.83 Mn |
| Sep 30, 2022 | -8.43 Mn |
| Jun 30, 2022 | -10.87 Mn |
| Mar 31, 2022 | -10.49 Mn |
| Dec 31, 2021 | 199,000.00 |
| Sep 30, 2021 | -2.34 Mn |